In the version of this article initially published, ref. 10 was cited twice and has been replaced by an omitted reference (Faivre E. J. et al. Cancer Re s. https://doi.org/10.1158/1538-7445.AM2024-3148 (2024)), now cited as ref. 11 in the last paragraph of the introduction: “Preclinical studies in patient-derived xenograft models of SEZ6-positive SCLC demonstrated superior activity of ABBV-706 compared to ABBV-011 and standard-of-care chemotherapies 10 . Preliminary results from the ongoing first-in-human phase 1 trial ( NCT05599984 ) to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 in patients with R/R solid tumors (defined as those patients whose disease had progressed on or after treatment with standard of care), including patients with R/R SCLC, demonstrated that ABBV-706 monotherapy had a manageable safety profile and promising antitumor activity, with a confirmed ORR of 43.8% (60.9% in patients with R/R SCLC) 11 .” The reference has been updated in the HTML and PDF version of the article.
Byers et al. (2026) studied this question.